Astrazeneca's (AZN) rare disease group Alexion Pharma Canada said Wednesday it signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for Koselugo to treat pediatric patients aged at least two years with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
With the agreement in place, individual provinces and territories in Canada may now start the procedure to list Koselugo on their formularies, Alexion Pharma said.
Financial terms were not disclosed.
Price: 66.36, Change: -0.82, Percent Change: -1.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments